Tempest Therapeutics (NASDAQ:TPST) Receives “Outperform” Rating from William Blair

William Blair reiterated their outperform rating on shares of Tempest Therapeutics (NASDAQ:TPST) in a research report sent to investors on Wednesday morning,RTT News reports.

Separately, HC Wainwright restated a “buy” rating and issued a $47.00 price target on shares of Tempest Therapeutics in a research report on Wednesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $20.00.

Tempest Therapeutics Trading Down 10.5 %

TPST opened at $0.97 on Wednesday. Tempest Therapeutics has a fifty-two week low of $0.86 and a fifty-two week high of $6.00. The company has a market cap of $24.37 million, a price-to-earnings ratio of -0.63 and a beta of -1.78. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.17 and a quick ratio of 2.17. The firm has a 50 day simple moving average of $1.20 and a 200 day simple moving average of $1.96.

Hedge Funds Weigh In On Tempest Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP acquired a new stake in Tempest Therapeutics during the 2nd quarter worth $55,000. Virtu Financial LLC lifted its holdings in shares of Tempest Therapeutics by 69.2% during the 1st quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock valued at $112,000 after purchasing an additional 11,689 shares in the last quarter. Empower Advisory Group LLC acquired a new position in shares of Tempest Therapeutics in the 3rd quarter valued at approximately $49,000. Finally, Fullcircle Wealth LLC bought a new stake in Tempest Therapeutics during the 3rd quarter worth approximately $87,000. 22.52% of the stock is owned by institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.